[The poor chemotherapeutic efficacy in lung adenocarcinoma overexpressing c-Src and nucleophosmin/B23(NPM1)].
Objective To observe the expressions of c-Src protein and nucleophosmin/B23 (NPM1) protein in lung adenocarcinoma tissues and explore their relationships with chemotherapeutic efficacy. Methods The study collected a total of 107 lung adenocarcinoma tissue specimens from the First People's Hospital of Huaihua City from 2012-10-10 to 2015-06-30. Immunohistochemistry was used to analyze the expressions of c-Src protein and NPM1 protein. The relationships between the protein expressions and lung adenocarcinoma progression were subsequently analyzed. Among these patients, 55 cases of III-IV patients were treated with gemcitabine combined with cisplatin for 4 cycles of chemotherapy. The relationships between the protein expressions and chemotherapeutic efficacy were then analyzed. Results Both c-Src protein and NPM1 protein were positively expressed in lung adenocarcinoma tissues. With the increase of clinical stages, their expression levels gradually increased. However, their levels showed an inverse correlation with tumor differentiation degree. Chemotherapeutic efficacy decreased with the increase of the protein expressions. Conclusion Chemotherapeutic sensitivity is poor in lung adenocarcinoma patients overexpressing c-Src and NPM1 protein. High expressions of c-Src and NPM1 may be associated with poorly differentiated adenocarcinoma.
Department of Respiration Medicine, Huaihua 418000, China. E-mail: hjb0919@aliyun.com.
Jianbin
J
He
Department of Respiration Medicine, Huaihua 418000, China.
Zhi
Z
Xiang
Department of Oncology, Huaihua 418000, China.
Jiwen
J
Xiao
Department of Pathology, Huaihua First People's Hospital, Huaihua 418000, China.
Haibo
H
Xiao
Department of Clinical Medicine, Hunan University of Medicine, Huaihua 418000, China.
Lijing
L
Liu
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D000077192:Adenocarcinoma of Lung; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D000081247:CSK Tyrosine-Protein Kinase; D002945:Cisplatin / Q000008:administration & dosage; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009687:Nuclear Proteins / Q000235:genetics* / Q000378:metabolism; D000090243:Nucleophosmin; D016896:Treatment Outcome; D019061:src-Family Kinases / Q000235:genetics* / Q000378:metabolism; D000093542:Gemcitabine
D000970:Antineoplastic Agents; C000716967:NPM1 protein, human; D009687:Nuclear Proteins; D003841:Deoxycytidine; D000090243:Nucleophosmin; D000081247:CSK Tyrosine-Protein Kinase; D019061:src-Family Kinases; C000631346:CSK protein, human; D002945:Cisplatin; D000093542:Gemcitabine